• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Prasinezumab therapy does not affect Parkinson’s Disease progression

byDavid XiangandKiera Liblik
August 12, 2022
in Chronic Disease, Neurology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Prasinezumab had no meaningful effect on global or imaging measures of Parkinson’s disease progression.

2. Prasinezumab therapy was associated with increased infusion reactions compared to placebo.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Aggregated a-synuclein is a main factor in the pathogenesis of Parkinson’s disease. Prasinezumab was designed as a monoclonal antibody to bind aggregated a-synuclein at the C-terminal selectively. In phase one trials, Prasinezumab has been demonstrated to show brain penetration. Further, it has resulted in dose-dependent reductions from baseline free serum a-synuclein levels. However, there is a knowledge gap in understanding the efficacy and safety of low dose (1500mg) and high dose (4500 mg) Prasinezumab in patients with early-stage Parkinson’s disease. Overall, the present study found that treatment with Prasinezumab had no meaningful effect on global clinical or imaging measures of Parkinson’s disease progression. This study was limited by the planned censoring of data from participants when they started treatment for symptoms of Parkinson’s disease. The trial population was also not representative of the wider population of persons with Parkinson’s disease, as non-White, non-United States, and non-European populations were underrepresented. Nevertheless, the study’s findings are significant, as they demonstrate that Prasinezumab has no clinically meaningful effect on early-stage Parkinson’s disease progression.

Click to read the study in NEJM

Relevant Reading: Randomized Trial of Focused Ultrasound Subthalamotomy for Parkinson’s Disease

In-Depth [randomized control trial]: This randomized phase two trial assigned participants with early-stage Parkinson’s disease in a 1:1:1 ratio to receive either intravenous placebo, low-dose Prasinezumab, or high-dose Prasinezumab every four weeks for 52 weeks. Patients who had early-stage Parkinson’s disease, findings on dopamine transporter imaging with SPECT that were consistent with Parkinson’s, and no previous treatment for symptoms of Parkinson’s disease were eligible for the study. The primary outcome measure was the change from baseline to week 52 in the sum of scores of the Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), with higher scores indicating greater impairment. Outcomes in the primary analysis were assessed via pairwise comparison and efficacy analyses. Based on the primary analysis, the mean changes in the MDS-UPDRS scores were 9.4+/-1.2 in the placebo group, 7.4+/-1.2 in the low-dose Prasinezumab group (difference versus placebo, -2.0; 80% Confidence Interval [CI], -4.2 to 0.2), and 8.8+/-1.2 in the high dose Prasinezumab group (difference versus placebo, -0.6; 80% CI -2.8 to 1.6). There was no significant difference between the Prasinezumab treatment groups and the placebo group in dopamine transporter levels on SPECT. Moreover, infusion reactions occurred in 19% of the low dose group and in 34% of the high dose Prasinezumab group. Overall, this study demonstrates that Prasinezumab has no significant nor clinically meaningful effect on global or imaging measures of Parkinson’s disease progression, suggesting it is not an effective therapy for preventing or slowing the progression of early-stage Parkinson’s disease.

RELATED REPORTS

Left atrial reservoir strain improves ischemic stroke risk prediction in low-risk patients

Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease

Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: a-synucleinAggregated a-synucleinchronic diseasedegenerative diseaseneurological diseaseneurologyParkinson’sParkinson’s DiseasePrasinezumab
Previous Post

Prior syncope presentation not associated with increased risk of motor vehicle collision

Next Post

Vitamin D deficiency may be associated with sleep disorders in children

RelatedReports

Intensive rehabilitation not superior to traditional therapy for arm function after stroke
Cardiology

Left atrial reservoir strain improves ischemic stroke risk prediction in low-risk patients

January 31, 2023
Resection of colorectal liver metastases may improve cost and longevity
Chronic Disease

Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease

January 30, 2023
β-blockers linked to improved survival in preserved ejection fraction heart failure
Cardiology

Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia

January 27, 2023
Brain lesions on MRI linked with subsequent increased stroke risk
Chronic Disease

Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia

January 27, 2023
Next Post
Parents with poor sleep quality report sleep problems in kids

Vitamin D deficiency may be associated with sleep disorders in children

Adalimumab aids in control of noninfectious uveitis

Daily disposable contact lenses may lower risk for Acanthamoeba keratitis

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]

LI-RADS outlines standards for liver imaging studies assessing HCC [Classics Series]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Extracorporeal and conventional cardiopulmonary resuscitation have similar effects on neurologic outcome in patients with refractory out-of-hospital cardiac arrest
  • Rocatinlimab may be effective in the treatment of moderate-to-severe atopic dermatitis
  • Gender-affirming hormones improve psychosocial functioning in transgender youth
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options